Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic

Blood (2023) 142 (Supplement 1): 427.

https://doi.org/10.1182/blood-2023-179812

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 Agonist-Based Adjuvant and Anti-PD-L1 Antibody

Sungho Moon, Miyeon Chun, Sangwoo Kim, Hanna Seo, Kyeong eun Kim, Geummi Cho, Chul Kim, Dok Hyun Yoon, Yoon Se Lee, Tae Min Kim, Eun-Jae Chung, Junho Chung

Blood (2023) 142 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2023-185255

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar

Blood (2022) 140 (Supplement 1): 9464–9467.

https://doi.org/10.1182/blood-2022-157679

Published: 2022

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood (2022) 140 (Supplement 1): 1070–1071.

https://doi.org/10.1182/blood-2022-158406

Published: 2022

Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood (2022) 140 (Supplement 1): 2280–2282.

https://doi.org/10.1182/blood-2022-158404

Published: 2022

Journal Articles

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Paolo Strati, Tae Min Kim, Alexey V Danilov, Chan Y. Cheah, Dok Hyun Yoon, Wojciech Jurczak, Shringi Sharma, Jeong Lim Yoon, Serena Arduini, Jamal Saeh, Richard F. Olsson, Gareth Gregory

Blood (2022) 140 (Supplement 1): 6656–6658.

https://doi.org/10.1182/blood-2022-165979

Published: 2022

Journal Articles

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Tae Min Kim, Dok Hyun Yoon, Ahmad H. Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, Seok Jin Kim

Blood (2021) 138 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2021-149927

Published: 2021

Journal Articles

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Burhan Ferhanoglu, Marta Zerga, Mubarak Al-mansour, Tae Min Kim, Su-Peng Yeh, Yuqin Song, Amado J Karduss, Gayane Tumyan, Soon Thye Lim, Silvia Rivas-Vera, Yok Lam Kwong, Kwang-Wei Wu, Zhongwen Huang, Mark Hertzberg

Blood (2021) 138 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2021-145838

Published: 2021

Journal Articles

Low Density of CD3+ Tumor-Infiltrating Lymphocytes Is Predictive of a Poor Prognosis in Diffuse Large B-Cell Lymphoma Independently of MYC and BCL2 Double Expression Status: A Potential Utility of Immunoscore Based on Whole-Slide Image Analysis

Bogyeong Han, Jeemin Yim, Sojung Lim, Cheol Lee, Tae Min Kim, Kim Sehui, Yoon Kyung Jeon

Blood (2021) 138 (Supplement 1): 2523.

https://doi.org/10.1182/blood-2021-154204

Published: 2021

Journal Articles

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-136295

Published: 2020

NARROW

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 Agonist-Based Adjuvant and Anti-PD-L1 Antibody

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Low Density of CD3+ Tumor-Infiltrating Lymphocytes Is Predictive of a Poor Prognosis in Diffuse Large B-Cell Lymphoma Independently of MYC and BCL2 Double Expression Status: A Potential Utility of Immunoscore Based on Whole-Slide Image Analysis

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only